FL
Insider
Fairmount Funds Management LLC
DirectorFairmount Funds Management LLC (Director) filed 10 Form 4 reports as a reporting entity in the trailing twelve months (6 purchases, 4 sales), most often in Cogent Biosciences, Inc. (COGT). Across 6 priced purchase filings, the average 21-session return was +5.9% from execution and +8.5% from disclosure (delay-adjusted; derived). The largest single filing was $399.7M of SYRE (4,684,781 sh × $85.31, as filed), executed Jun 23.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+5.9%
avg across 6 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+8.5%
same 6 filings, from disclosure
Filings, ttm
10
6 buys · 4 sells
Median delay
3d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$1.1B
shares × price, as filed
Last traded
Jul 16
Filed Jul 20
Median ADV $84.0M across their filed names
Impact on $10,000 · 12M
$12,544 (+25.4%)
S&P 500 $11,725 (+17.2%) · 8.2 pts ahead
Fairmount Funds Management LLC
S&P 500
Compounded across filings from disclosure dates · past 12 months
Open performance→Volume by month
Buys $94.6M
Sells $1.1B
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
10 filings
Sector per market data · by filing · past 12 months
Most traded names
COGTRecent filings
VRDNPURCHASE
Viridian Therapeutics, Inc.
View filing →
$10.0M454,545 sh × $22.00
Exec Oct 23 2025
Filed Oct 27 2025 · 4:30 PM ET ZBIOPURCHASE Zenas BioPharma, Inc. View filing → $6.0M
316,219 sh × $19.00
Exec Oct 7 2025
Filed Oct 9 2025 · 4:15 PM ET COGTPURCHASE Cogent Biosciences, Inc. View filing → $25.0M
2,777,777 sh × $9.00
Exec Jul 10 2025
Filed Jul 14 2025 · 5:30 PM ET ZBIOPURCHASE Zenas BioPharma, Inc. View filing → $5.1M
300,000 sh × $17.00
Exec Sep 16 2024
Filed Sep 17 2024 · 5:30 PM ET